DDInter1758 DDInter1376
Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Telithromycin {u} (Compound) resembles {v} (Compound) Azithromycin
Telithromycin {u} (Compound) binds {v} (Gene) CYP1A2
Telithromycin {u} (Compound) is included by {v} (Pharmacologic Class) Ketolides
Telithromycin {u} (Compound) causes {v} (Side Effect) Bundle branch block
Telithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Telithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paricalcitol
Telithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexamethasone
Telithromycin {u} may lead to a major life threatening interaction when taken with {v} Betrixaban
Telithromycin {u} may lead to a major life threatening interaction when taken with {v} Terfenadine
Telithromycin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Telithromycin (Compound) resembles Azithromycin (Compound)
Telithromycin (Compound) binds CYP1A2 (Gene)
Telithromycin (Compound) is included by Ketolides (Pharmacologic Class)
Telithromycin (Compound) causes Bundle branch block (Side Effect)
Telithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Paricalcitol
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Telithromycin may lead to a major life threatening interaction when taken with Betrixaban
Telithromycin may lead to a major life threatening interaction when taken with Terfenadine
Telithromycin (Compound) resembles Clarithromycin (Compound) and Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin